The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.
The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development.
Browse the Report Summary at: www.psmarketresearch.com/market-an…rapeutics-market
As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor.
U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.
The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF.
Some of the key players developing drugs candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.
Explore Report Sample at: www.psmarketresearch.com/market-an…et/report-sample
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: